ESR1 and breast cancer: GDC-0810 (ARN-810) is a novel, non-steroidal, orally bioavailable SERD that binds to the ER to limit the activity of estrogen and also induces conformational changes leading to receptor degradation, thereby combating ligand-dependent as well as ligand-independent ER signaling in ER + breast cancer.